` XAIR (Beyond Air Inc) vs S&P 500 Comparison - Alpha Spread

XAIR
vs
S&P 500

Over the past 12 months, XAIR has underperformed S&P 500, delivering a return of -71% compared to the S&P 500's +16% growth.

Stocks Performance
XAIR vs S&P 500

Loading
XAIR
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
XAIR vs S&P 500

Loading
XAIR
S&P 500
Difference
www.alphaspread.com

Performance By Year
XAIR vs S&P 500

Loading
XAIR
S&P 500
Add Stock

Competitors Performance
Beyond Air Inc vs Peers

Beyond Air Inc
Glance View

Market Cap
15.8m USD
Industry
Health Care

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. The company is headquartered in Garden City, New York and currently employs 45 full-time employees. The company went IPO on 2019-05-07. The firm is engaged in developing a nitric oxide (NO) generator and delivery system through its LungFit platmorfm that is capable of generating NO from ambient air. Its pipeline includes LungFit PH designed to deliver a dosage of NO to the lungs for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), LungFit PRO for the treatment of viral lung infections for adults, which is commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus and LungFit GO for the treatment of rare and serious pulmonary disease associated with increased morbidity and mortality called Nontuberculous mycobacteria (NTM) lung infection.

XAIR Intrinsic Value
16.74 USD
Undervaluation 80%
Intrinsic Value
Price
Back to Top